Wird geladen...

Feasibility, Tolerability and Efficacy of Carfilzomib in Combination with Lenalidomide and Dexamethasone in Relapsed Refractory Myeloma Patients: A Retrospective Real-Life Survey of the Sicilian Myeloma Network

Background: The ASPIRE (NCT01080391) phase 3 trial showed the efficacy of carfilzomib, lenalidomide and dexamethasone (KRd) triplet for relapse and refractory multiple myeloma (RRMM). However, little is known about safety and efficacy of KRd outside a clinical trial context. Methods: Herein we repor...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:J Clin Med
Hauptverfasser: Conticello, Concetta, Romano, Alessandra, Del Fabro, Vittorio, Martino, Enrica Antonia, Calafiore, Valeria, Sapienza, Giuseppe, Leotta, Valerio, Parisi, Marina Silvia, Markovic, Uros, Garibaldi, Bruno, Leotta, Salvatore, Cotzia, Emilia, Innao, Vanessa, Mannina, Donato, Neri, Santo, Musso, Maurizio, Scalone, Renato, Cangialosi, Clotilde, Acquaviva, Francesco, Cardinale, Giovanni, Merenda, Anxur, Maugeri, Cinzia, Uccello, Giuseppina, Poidomani, Massimo, Longo, Giuseppe, Carlisi, Melania, Tibullo, Daniele, Di Raimondo, Francesco
Format: Artigo
Sprache:Inglês
Veröffentlicht: MDPI 2019
Schlagworte:
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC6617295/
https://ncbi.nlm.nih.gov/pubmed/31248142
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/jcm8060877
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!